Platelet P2 receptors: Old and new targets for antithrombotic drugs

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 45-55

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ADP; Antiplatelet agents; ATP; Clopidogrel; P2 receptors; Platelets; Prasugrel; Thienopyridines; Thrombosis; Ticlopidine

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANTICOAGULANT AGENT; AR C 109318XX; ARC 69931; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; DRUG METABOLITE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y1 RECEPTOR ANTAGONIST; PURINE P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; R 138727; R 99224; RECEPTOR BLOCKING AGENT; THIENOPYRIDINE; THROMBOCYTE RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

APLASTIC ANEMIA; ATHEROSCLEROSIS; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INCIDENCE; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ANGINA, UNSTABLE; ANIMALS; BLOOD PLATELETS; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PURINERGIC P2; SYNDROME; THIOPHENES; TICLOPIDINE;

EID: 33846533006     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.45     Document Type: Review

References (67)

1. Abbracchio MP, Boeynaems J-M, Barnard EA. Boyer JL, Kennedy C, Characterization of the UDP-glucose receptor (re-named the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci. 24, 52-55 (2003)
2. Boeynaems J-M, Communi D, Suarez Gonzales N, Robaye B. Overview of the P2 receptors. Sem. Thromb. Hemost. 31, 139-149 (2005).
3. Cattanoe M. The platelet P2 receptors. In: Platelets. Michelson AD (Ed.), Academic Pre, San Diego, CA, USA, 2006. In press.
4. Gachet C. Regulation of platelet functions by P2 receptors. Ann. Rev. Pharmacol. Toxicol. 46, 277-300 (2006)
5. Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha, beta-methylene ATP. Thromb. Haemost, 85(2), 303-308 (2001).
6. Cattaneo M, Marchese P Jacobson KA, Ruggeri Z. New insights into the role of P2X1 in platelet function (abstract). Haematologica 87, 13-14 (2002).
7. Cattaneo M, Marchese P, Jacobson KA, Ruggeri ZM. The P2X1 receptor for ATP plays an essential role in platelet agregation at high shear. Haematology J. 4(Suppl. 2), 150 (2003).
8. Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb. Haemost. 86(5), 1264-1271 (2001).
9. 2+-calmodulin and myosin fight chain kinase activation. J. Biol. Chem. 279(25), 26266-26273 (2004).
10. Cattaneo M. ADP receptors antagonists. In: Platelets Michelson AD (Ed.), Academic Press, San Diego, CA, USA 2006. In press.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996).
12. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354 (online ahead publication, March 12, 2006).
13. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1(8649), 1215-1220 (1989).
14. Hass WK, Easton JD, Adams HP Jr et al. randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321(8), 501-507 (1989).
15. Gorelick PB, Richardson D, Kelly M et al. African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 289(22), 2947-2957 (2003).
16. Diener HC, Bogousslavsky J, Brass L.M, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364, 331-337 (2004).
17. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev. 2, CD001246 (2000).
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med 345(7), 494-502 (2001).
19. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med 352(12),1179-1189 (2005).
20. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
21. Schornig A, Neumann FJ, Kastrati A. Schuhlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334(17), 1084-1089 (1996).
22. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98(16), 1597-1603 (1998).
23. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98(20), 2126-2132 (1998).
24. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339(23), 1665-1671 (1998).
25. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 358, 527-533 (2001).
26. Steinhubl SR, Berger PB, Mann JT 3rd et al. Clopidogrel fbr the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
27. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-devation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 294(10), 1224-1232(2005).
28. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedurat myocardial infarction in patients undergoing coronaryintervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 111(16), 2099-2106 (2005).
29. Kastrati A. Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350(3), 232-238 (2004).
30. Kastrati A, Mehilli J, Newmann FJ et al; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISARREACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 295(13), 1531-1538 (2006).
31. Bhatt DL, Bertrand ME, Berger PB et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. 39(1), 9-14 (2002).
32. Mueller C, Roskamm H, Neumann FJ et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J. Am. Coll. Cardiol. 41(6), 969-973 (2003).
33. Wolak A, Amit G, Cafri C, Gilutz H, Ilia R, Zahger D. Increased long-term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. Int. J. Cardiol. 103(3), 293-297 (2005).
34. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227(5), 301-308 (1990).
35. ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 367, 1903-1912 (2006).
36. Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. J. Med. 346(23), 1800-1806 (2002).
37. Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study. Pharmacoeconomics. 22 Suppl. 4. 19-27 (2004).
38. Karnon J, Brennan A, Pandor A et al. Modelling the long-term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr. Med. Res. Opin. 21(1), 101-112 (2005).
39. Beinart SC, Kolm P, Veledar E et al. Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. J. Am. Coll. Cardiol. 46(5), 761-769 (2005).
40. Cowper PA, Udayakumar K, Sketch MH Jr, Peterson ED. Economic effects of prolonged clopidogrel therapy after percutaneous coronary Intervention. J. Am. Coll. Cardiol. 45 (3), 369-376 (2005).
41. Karnon J, Bakhai A, Brennan A, Flather M, Warren E, Gray D, Akehurst R. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int. J. Cardiol. 2005 Jul 15; [EPUB AHEAD OF PRINT]
42. Lamy A, Jonsson B, Weintraub WS et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur. J. Cardiovasc. Prev. Rehabil. 11(6), 460-465 (2004).
43. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: A long-term model based on the CURE trial. J. Interm. Med. 255(5), 562-570 (2004).
44. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med. 142(4), 251-259 (2005).
45. Weintraub WS, Mahoney EM, Lamy A et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J. Am. Coll. Cardiol. 45(6), 838-845 (2005).
46. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol. 24, 1980-1987 (2004).
47. Taubert D, Kastrati A, Harlfinger S et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 92(2), 311-316 (2004).
48. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 16(3), 199-204 (2005).
49. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (Prasugrel, LY-60315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Sem. Thromb. Hemost. 31, 184-194 (2005).
50. Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY-640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 111(25), 3366-3373 (2005).
51. van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem. Thromb. Hemost. 31, 195-204 (2005).
52. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931 MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. 85, 401-407 (2001).
53. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 13(7), 407-413 (2002).
54. Beham M, Fox S, Sanderson H, Storey R, Heptinstall S. Effect of Clopidogrel on procoagulant activity in acute coronary syndromes: Evidence for incomplete P2Y12 receptor blockade. Circulation. 106, II 149-II 150 (2002).
55. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmakodynamic, pharmacokinetic and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) (In Press).
56. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S et al. Anti-aggregatory activity in human platelets of potent antagonists of the P2Y(1) receptor. Biochem. Pharmacol. 68(10), 1995-2002 (2004).
57. 1 receptor, with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther. 316(2), 556-563 (2006).
58. Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: Evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol. 13(1), 108-114 (2000).
59. Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J. Biol. Chem. 278(47), 46661-46667 (2003).
60. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood. 100(7), 2499-2505 (2002).
61. Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J. Exp. Med. 198(4), 661-667 (2003).
62. Erhardt JA, Pillarisetti K, Toomey JR. Potentiation of platelet activation through the stimulation of P2X1 receptors. J. Thromb. Haemost. 1(12), 2626-2635 (2003).
63. Kawa K. Thrombopoietin enhances rapid current responses mediated by P2X1 receptors on megakaryocytic cells in culture. Jpn. J. Physio.l 153, 287-299 (2003).
64. 2+ responses of human platelets. Thromb. Haemost. 94(1), 37-40 (2005).
65. Mulryan K, Gitterman DP, Lewis CJ et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403, 86-89 (2000).
66. Hechler B, Magnenat S, Zighetti ML et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4′,4",4"'-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetrakisbenzene-1,3-disulfonicacidoctasodiumsalt]. J. Pharmacol. Exp. Ther. 314(1), 232-43 (2005).
67. Horner S, Menke K, Hildebrandt C et al. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the nanomolar range. Naunyn-Schmiedebergs Arch. Pharmacol. 372, 1-13 (2005).